Oragenics Inc (OGEN)

[conix]

OGEN INVESTMENT HIGHLIGHTS:

*Near-term catalysts for ongoing clinical program or AG013 and Oral Mucositis

*Large unmet clinical need - NO DRUG APPROVED to prevent OM in a broad cancer population

*Large addressable market - Over 750,000 per year in U.S.

*Most common and debilitating complication of cancer chemo and radiation therapy

*Inability to eat or drink results in weight loss/energy during treatment

*Potential Worldwide sales greater than $2.0 billion; High margins

*Company has novel Lantibiotic Platform for Multidrug resistant bacterial infections

Listing: OGEN-NASDAQ
Price: $.68
H-L:$0.35 - 0.99
Market Cap: $32MM

Profile:

Oragenics is focused on developing effective treatments for oral mucositis and becoming a leader in developing novel antibiotics against infectious diseases. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

Website: www.oragenics.com